Thyroid Disorders and Hypercoagulability

ABSTRACT

Various abnormalities of coagulation and fibrinolysis, ranging from subclinical laboratory abnormalities to clinically significant disorders of hemostasis, but rarely major hemorrhage or thromboembolism, may occur in patients with thyroid diseases. This review discusses the relationships between thyroid dysfunction and the coagulation/fibrinolytic system. According to the recent literature, most of the coagulation/fibrinolytic abnormalities associated with thyroid dysfunction are the consequences of direct effects of thyroid hormones on the synthesis of various hemostatic parameters. Thyroid autoimmunity may also modify the processes of secondary hemostasis. Hyperthyroidism is generally associated with hypercoagulability and hypofibrinolysis, whereas the hemostatic profile in hypothyroidism depends on the severity of the disease. Both hypercoagulable and hypocoagulable states including increased fibrinolytic activity have been reported in hypothyroidism. Few data are available on hemostasis in subclinical thyroid diseases. In conclusion, adequate further prospective clinical studies of high quality including a larges series of patients are needed to explain the degree and type of coagulation/fibrinolytic abnormalities in patients with thyroid diseases.

KEYWORDS

Thyroid - hypercoagulability - hyperthyroidism - hypothyroidism

REFERENCES

• 1 Hulbert A J. Thyroid hormones and their effects: a new perspective.  Biol Rev Camb Philos Soc. 2000;  75 (4) 519-631
• 2 Spronk H M, van der Voort D, Ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship.  Thromb J. 2004;  2 (1) 12
• 3 Thomas D P, Roberts H R. Hypercoagulability in venous and arterial thrombosis.  Ann Intern Med. 1997;  126 (8) 638-644
• 4 Squizzato A, Gerdes V E, Brandjes D P, Büller H R, Stam J. Thyroid diseases and cerebrovascular disease.  Stroke. 2005;  36 (10) 2302-2310
• 5 Squizzato A, Romualdi E, Büller H R, Gerdes V E. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review.  J Clin Endocrinol Metab. 2007;  92 (7) 2415-2420
• 6 Hofbauer L C, Heufelder A E. Coagulation disorders in thyroid diseases.  Eur J Endocrinol. 1997;  136 (1) 1-7
• 7 Franchini M. Hemostatic changes in thyroid diseases: haemostasis and thrombosis.  Hematology. 2006;  11 (3) 203-208
• 8 Erem C, Kavgacı H, Ersöz HÖ et al. Blood coagulation and fibrinolytic activity in hypothyroidism.  Int J Clin Pract. 2003;  57 (2) 78-81
• 9 Franchini M, Lippi G, Manzato F, Vescovi P P. Thyroid-associated autoimmune coagulation disorders.  J Thromb Thrombolysis. 2010;  29 (1) 87-91
• 10 Franchini M, Montagnana M, Manzato F, Vescovi P P. Thyroid dysfunction and hemostasis: an issue still unresolved.  Semin Thromb Hemost. 2009;  35 (3) 288-294
• 11 Franchini M. Hemostasis and thyroid diseases revisited.  J Endocrinol Invest. 2004;  27 (9) 886-892
• 12 Franchini M, Lippi G, Manzato F, Vescovi P P, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders.  Eur J Endocrinol. 2010;  162 (3) 439-451
• 13 Mina A, Favaloro E J, Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.  Semin Thromb Hemost. 2007;  33 (8) 798-809
• 14 Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism.  J Clin Endocrinol Metab. 2007;  92 (8) 3006-3012
• 15 Erem C, Kavgacı H, Ersöz HÖ et al. Blood coagulation and fibrinolytic activity in hypothyroidism.  Int J Clin Pract. 2003;  57 (2) 78-81
• 16 Akinci B, Comlekci A, Ali Ozcan M et al.. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.  Endocr J. 2007;  54 (1) 45-52
• 17 Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz H O. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.  Endocrine. 2009;  35 (1) 75-80
• 18 Cetinkalp S, Tobu M, Karadeniz M, Buyukkeçeci F, Yilmaz C. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis.  Intern Med. 2009;  48 (5) 281-285
• 19 Dai A, Wasay M, Dubey N, Giglio P, Bakshi R. Superior sagittal sinus thrombosis secondary to hyperthyroidism.  J Stroke Cerebrovasc Dis. 2000;  9 (2) 89-90
• 20 Squizzato A, Vitale J, Gerdes V E, Romualdi E, Büller H R, Ageno W. Recurrent deep venous thrombosis during optimal anticoagulation and overt hyperthyroidism: a case report.  Blood Coagul Fibrinolysis. 2007;  18 (8) 801-803
• 21 Danescu L G, Badshah A, Danescu S C et al. Venous thromboembolism in patients hospitalized with thyroid dysfunction.  Clin Appl Thromb Hemost. 2009;  15 (6) 676-680
• 22 Marongiu F, Conti M, Murtas M L et al. Anticardiolipin antibodies in Graves' disease: relationship with thrombin activity in vivo.  Thromb Res. 1991;  64 (6) 745-749
• 23 Hofbauer L C, Spitzweg C, Heufelder A E. Graves' disease associated with the primary antiphospholipid syndrome.  J Rheumatol. 1996;  23 (8) 1435-1437
• 24 Erem C, Ersoz HÖ, Kartı S S et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism.  J Endocrinol Invest. 2002;  25 (4) 345-350
• 25 Burggraaf J, Lalezari S, Emeis J J et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazole.  Thyroid. 2001;  11 (2) 153-160
• 26 Lodha A, Haran M, Frankel R, Shani J. Thyrotoxicosis causing arterial and venous thrombosis.  Am J Med Sci. 2009;  338 (5) 428
• 27 Rogers II J S, Shane S R, Jencks F S. Factor VIII activity and thyroid function.  Ann Intern Med. 1982;  97 (5) 713-716
• 28 Marongiu F, Conti M, Mameli G et al. Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment.  J Endocrinol Invest. 1988;  11 (10) 723-725
• 29 Lippi G, Franchini M, Targher G et al. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients.  J Thromb Thrombolysis. 2009;  28 (3) 362-365
• 30 Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci P M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.  Blood. 2004;  104 (12) 3631-3634
• 31 Soma M, Maeda Y, Matsuura R et al. Study of serum thrombomodulin(TM) levels in patients with hyper- or hypo- thyroidism [in Japanese].  Rinsho Byori. 1997;  45 (1) 77-81
• 32 Liu L, Wang X, Lin Z, Wu H. Elevated plasma levels of VWF:Ag in hyperthyroidism are mediated through beta-adrenergic receptors.  Endocr Res. 1993;  19 (2-3) 123-133
• 33 Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz H O. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.  Endocrine. 2009;  36 473-478
• 34 Morikawa Y, Morikawa A, Makino I. Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves' disease: TM, a possible new marker of the peripheral activity of thyroid hormones.  J Clin Endocrinol Metab. 1993;  76 (3) 609-614
• 35 Ozcan M A, Cömlekçi A, Demirkan F et al. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders.  Thromb Res. 2003;  110 (4) 243-247
• 36 Akinci B, Comlekci A, Yener S et al. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.  Endocr J. 2007;  54 (4) 593-599
• 37 Takahashi A, Tamura A, Ishikawa O. Antiphospholipid antibody syndrome complicated by Graves' disease.  J Dermatol. 2002;  29 (12) 776-780
• 38 Porter L, Mandel S J. The blood in thyrotoxicosis. In, Braverman L E, Utiger R D, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 627-631
• 39 Paggi A, Caccavo D, Ferri G M et al.. Anticardiolipin antibodies in autoimmune thyroid disease.  Clin Endocrinol (Oxf). 1994;  140 329-333
• 40 Dagenais P, Urowitz M B, Gladman D D, Norman C S. A family study of the antiphospholipid syndrome associated with other autoimmune diseases.  J Rheumatol. 1992;  19 (9) 1393-1396
• 41 Sawin C T, Geller A, Wolf P A et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.  N Engl J Med. 1994;  331 (19) 1249-1252
• 42 Jayaprasad N, Francis J. Atrial fibrillation and hyperthyroidism.  Indian Pacing Electrophysiol J. 2005;  5 (4) 305-311
• 43 Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation.  Arch Intern Med. 1981;  141 (9) 1191-1192
• 44 Osman F, Gammage M D, Sheppard M C, Franklyn J A. Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace?.  J Clin Endocrinol Metab. 2002;  87 (3) 963-967
• 45 Presti C F, Hart R G. Thyrotoxicosis, atrial fibrillation, and embolism, revisited.  Am Heart J. 1989;  117 (4) 976-977
• 46 Marongiu F, Cauli C, Mariotti S. Thyroid, hemostasis and thrombosis.  J Endocrinol Invest. 2004;  27 (11) 1065-1071
• 47 Fuster V, Rydén L E, Cannom D S European Heart Rhythm Association et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).  J Am Coll Cardiol. 2006;  48 (4) 854-906
• 48 Simone J V, Abildgaard C F, Schulman I. Blood coagulation in thyroid dysfunction.  N Engl J Med. 1965;  273 (20) 1057-1061
• 49 Egeberg B O. Influence of thyroid function on the blood clotting system.  Scand J Clin Lab Invest. 1963;  15 1-7
• 50 Nordoy A, Vik-Mo H, Berntsen H. Haemostatic and lipid abnormalities in hypothyroidism.  Scand J Haematol. 1976;  16 (2) 154-160
• 51 Chadarevian R, Bruckert E, Ankri A, Beucler I, Giral P, Turpin G. Relationship between thyroid hormones and plasma D-dimer levels.  Thromb Haemost. 1998;  79 (1) 99-103
• 52 Thompson S G, Kienast J, Pyke S D, Haverkate F, van de Loo J C. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group . Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.  N Engl J Med. 1995;  332 (10) 635-641
• 53 Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.  J Clin Endocrinol Metab. 2001;  86 (2) 732-737
• 54 Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism.  Eur J Endocrinol. 2005;  152 (3) 355-361
• 55 Morishita E, Hashimoto T, Asakura H et al. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease.  Thromb Haemost. 1998;  79 (5) 919-923
• 56 Peralta A R, Canhão P. Hypothyroidism and cerebral vein thrombosis—a possible association.  J Neurol. 2008;  255 (7) 962-966
• 57 Marqusee E, Mandel S J. The blood in hypothyroidism. In, Braverman L E, Utiger R D, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 800-803
• 58 Meiklejohn D J, Watson H G. Acquired haemophilia in association with organ-specific autoimmune disease.  Haemophilia. 2001;  7 (5) 523-525
• 59 Hak A E, Pols H A, Visser T J, Drexhage H A, Hofman A, Witteman J C. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.  Ann Intern Med. 2000;  132 (4) 270-278
• 60 Dean J W, Fowler P B. Exaggerated responsiveness to thyrotrophin releasing hormone: a risk factor in women with coronary artery disease.  Br Med J (Clin Res Ed). 1985;  290 (6481) 1555-1561
• 61 Powell J, Zadeh J A, Carter G, Greenhalgh R M, Fowler P B. Raised serum thyrotrophin in women with peripheral arterial disease.  Br J Surg. 1987;  74 (12) 1139-1141
• 62 Müller B, Tsakiris D A, Roth C B, Guglielmetti M, Staub J J, Marbet G A. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease.  Eur J Clin Invest. 2001;  31 (2) 131-137
• 63 Cantürk Z, Cetinarslan B, Tarkun I, Cantürk N Z, Ozden M, Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism.  Thyroid. 2003;  13 (10) 971-977
• 64 Guldiken S, Demir M, Turgut B, Altun B U, Arikan E, Kara M. Global fibrinolytic capacity in patients with subclinical hypothyroidism.  Endocr J. 2005;  52 (3) 363-367
• 65 Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.  Clin Endocrinol (Oxf). 2006;  64 (3) 323-329
• 66 Patanè S, Marte F. Atrial fibrillation associated with subclinical hyperthyroidism.  Int J Cardiol. 2009;  134 (3) e155-e158
• 67 Singh S, Duggal J, Molnar J, Maldonado F, Barsano C P, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis.  Int J Cardiol. 2008;  125 (1) 41-48
• 68 Patanè S, Marte F, Di Bella G, Turiano G. Acute myocardial infarction and subclinical hyperthyroidism without significant coronary stenoses.  Int J Cardiol. 2009;  134 (3) e135-e137
• 69 Shih C H, Chen S L, Yen C C et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins.  Endocrinology. 2004;  145 (6) 2804-2814
• 70 Demir T, Akinci B, Comlekci A et al. Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation.  Clin Endocrinol (Oxf). 2009;  71 (3) 446-450
• 71 Tiede D J, Tefferi A, Kochhar R, Thompson G B, Hay I D. Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking.  Cancer. 1994;  73 (3) 702-705
• 72 Raveh E, Cohen M, Shpitzer T, Feinmesser R. Carcinoma of the thyroid: a cause of hypercoagulability?.  Ear Nose Throat J. 1995;  74 (2) 110-112
• 73 Sagripanti A, Carpi A, Baicchi U. The measurement of plasma D-dimer in the follow-up after thyroidectomy for cancer: preliminary data.  Thyroidology. 1991;  3 (1) 31-35
• 74 Lal G, Brennan T V, Hambleton J, Clark O H. Coagulopathy, marantic endocarditis, and cerebrovascular accidents as paraneoplastic features in medullary thyroid cancer—case report and review of the literature.  Thyroid. 2003;  13 (6) 601-605